Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
2(20%)
Results Posted
67%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph early_phase_1
2
20%
Ph phase_2
3
30%
Ph phase_1
2
20%
Ph not_applicable
1
10%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
2(22.2%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)
Other(3)

Detailed Status

Completed3
unknown2
Terminated2
Active, not recruiting2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (22.2%)
Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 31 (11.1%)
N/A1 (11.1%)

Trials by Status

suspended110%
unknown220%
completed330%
terminated220%
active_not_recruiting220%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruitingearly_phase_1

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

NCT03684980
active_not_recruitingearly_phase_1

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

NCT03960177
unknown

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

NCT05899751
suspendedphase_2

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

NCT04668768
unknownphase_1

Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma

NCT05135858
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03684980Early Phase 1

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

Active Not Recruiting
NCT03960177Early Phase 1

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

Active Not Recruiting
NCT05899751

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

Unknown
NCT04668768Phase 2

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

Suspended
NCT05135858Phase 1

Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma

Unknown
NCT01305655Phase 3

Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL

Completed
NCT02022358Phase 2

Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

Terminated
NCT00018967Not Applicable

Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate

Completed
NCT00634322Phase 2

High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma

Terminated
NCT00727831Phase 1

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10